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Abstract
Exposure of pregnant C3H/HeNCR mice to 42.5- or 85-ppm of arsenic as sodium arsenite in drinking
water between days 8 and 18 of gestation markedly increases tumor incidence in their offspring. In
the work reported here, distribution of inorganic arsenic and its metabolites, methyl arsenic and
dimethyl arsenic, were determined in maternal and fetal tissues collected on gestational day 18 of
these exposure regimens. Tissues were collected from three females and from associated fetuses
exposed to each dosage level. Concentrations of total speciated arsenic (sum of inorganic, methyl,
and dimethyl arsenic) were higher in maternal tissues than in placenta and fetal tissues; total speciated
arsenic concentration in placenta exceeded those in fetal tissues. Significant dosage-dependent (42.5
ppm versus 85 ppm of arsenite in drinking water) differences were found in total speciated arsenic
concentrations in maternal lung (p < 0.01) and liver (p < 0.001). Total speciated arsenic
concentrations did not differ significantly between dosage levels for maternal blood or for fetal lung,
liver, and blood, or for placenta. Percentages of inorganic, methyl, or dimethyl arsenic in maternal
or fetal tissues were not dosage-dependent. Over the range of total speciated arsenic concentrations
in most maternal and fetal tissues, dimethyl arsenic was the most abundant arsenical. However, in
maternal liver at the highest total speciated arsenic concentration, inorganic arsenic was the most
abundant arsenical, suggesting that a high tissue burden of arsenic affected formation or retention of
methylated species in this organ. Tissue concentration-dependent processes could affect kinetics of
transfer of inorganic arsenic or its metabolites from mother to fetus.
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Exposure to inorganic arsenic (iAs) has been associated with developmental and reproductive
toxicity (Willhite and Ferm, 1984), although such effects are dependent upon the route of
exposure (Holson et al., 2000). Because iAs is rapidly metabolized to methylated forms,
attribution of a particular adverse effect to a single arsenical species is problematic. In
experimental species, maternal exposure to inorganic arsenic (iAs) resulted in fetal exposure
to iAs and its metabolites, methyl arsenic (MAs) and dimethyl arsenic (DMAs) (Tanaka,
1976; Lindgren et al., 1982; Hood et al., 1987,1988). Exposure to MAs or DMAs produced
maternal and fetal toxicity and teratogenesis in rodents (Rogers et al., 1981; Hood, 1998),
suggesting that these arsenicals or their metabolites are the active forms. In women chronically
consuming iAs-contaminated drinking water during pregnancy, DMAs was the predominant
arsenical in either maternal or cord plasma (Concha et al., 1998); thus, iAs or its metabolites
must cross human placenta. Although evidence of teratogenesis is lacking in iAs-exposed
humans, reproductive toxicity has been reported in populations with high levels of exposure
to iAs. Chakraborti et al. (2003) found increased incidences of miscarriages, stillbirths, preterm
births, and low birth weights in offspring of women who used drinking water containing 463–
1025 μg iAs per l. Other studies of reproductive outcome in populations with high levels of
iAs exposure have revealed increased rates of spontaneous abortion and of perinatal and
neonatal mortality (Hopenhayn-Rich et al., 1998; Ahmad et al., 2001). Short and long-term
effects of transplacental exposure to iAs in humans have been reported. Ingestion of large doses
of iAs during pregnancy has been linked to intrauterine fetal death (Bolliger et al., 1992) and
to death of a premature infant (Lugo et al., 1969). The occurrence of multiple basilomata in a
young man has been associated with therapeutic use of Fowler’s solution (potassium arsenite)
by his mother during pregnancy (Aldick and Fabry, 1973).
Prominent among adverse health effects associated with chronic exposure to iAs in either
occupational or environmental settings is increased risk of cancer. An IARC review concluded
that there was sufficient evidence that arsenic in drinking water causes cancer of urinary
bladder, lung, and skin in exposed humans (IARC, 2004). By comparison, this review
concluded that there was only limited evidence that arsenite (iAsIII) was a carcinogen in
experimental species. Indeed, activity of iAsIII as a tumor promoter or as a carcinogen has been
demonstrated only in genetically modified animals or in animal models for co-carcinogenicity
(Germolec et al., 1998; Rossman, 2003). In contrast, exposure of fetal mice to iAsIII increases
cancer risk in later life. Apparently healthy offspring of C3H female mice that consumed
drinking water containing 42.5- or 85-ppm iAsIII between gestational days 8–18 developed
tumors in adult life (Waalkes et al., 2003,2004a). Tumor sites differed markedly between males
and females exposed in utero to iAsIII. Males showed dose-related increases in the number and
multiplicity of hepatocellular carcinomas; females showed dose-related increases in the
number and multiplicity of lung and ovary tumors. In addition, postnatal treatment with phorbol
ester in mice exposed in utero to iAsIII increased lung tumor yield in both sexes and liver tumor
yield in females (Waalkes et al., 2004b). In females exposed in utero to iAsIII, postnatal
exposure to diethylstilbestrol or tamoxifen increased the yield of uroepithelial proliferative
lesions or urogenital tumors (Waalkes et al., 2006). Hence, iAsIII is a complete transplacental
carcinogen and a tumor initiator in the fetal mouse.
Conversion of iAs to methylated metabolites is an enzymatically catalyzed process in which
oxidative methylation reactions using S-adenosylmethionine (AdoMet) as a methyl group
donor alternates with reactions in which arsenic is reduced from pentavalency to trivalency
(Cullen et al., 1984; Thomas et al., 2004). A single enzyme, arsenic (+3 oxidation state)
methyltransferase (AS3MT), plays a central role in the metabolic transformation of iAs to
methylated products (Lin et al., 2002). Because some intermediates and products (e.g.,
MAsIII and DMAsIII) formed in this metabolic pathway are more reactive and toxic than
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iAsIII, methylation of iAs is an activation process (Thomas et al., 2001). Thus, it is possible
that some of the adverse effects associated with in utero exposure to iAsIII could be mediated
by actions of iAs or by one of its reactive metabolites. In the work reported here, we have
quantified arsenicals in maternal and fetal tissues at the end of a regimen of exposure in
utero to iAs that has been shown to produce tumor development in adult life. Although
concentrations of arsenicals in maternal tissues and placenta exceeded those in fetal tissues,
relatively high concentrations of iAs, MAs, and DMAs were also present in fetal tissues. These
findings suggest that translocation of arsenicals from mother to fetus and metabolism of iAs
in fetal tissues may contribute to the accumulation of arsenicals in fetal tissues during critical
periods of growth and development.
2. Materials and methods
2.1. Chemicals
All reagents were prepared in deionized water (18 MΩ/cm). Only analytical grade chemicals
were used throughout the study, including sodium borohydride (NaBH4, EM Science,
Gibbstown, NJ), NaOH (EM Science), HCl (Fisher Chemicals, Fair Lawn, NJ), ultrapure
phosphoric acid (J.T. Baker, Inc., Phillipsburg, NJ), and antifoam B silicone emulsion (J.T.
Baker). ACS certified HNO3, H2SO4, HClO4, and HCl (all from EM Science) were used for
total arsenic analysis. Pentavalent arsenical standards for analysis by hydride generation-
atomic absorption spectrometry (HG-AAS) were arsenic acid, sodium salt (Sigma, St. Louis,
MO), methylarsonic acid, disodium salt (Chem Service, West Chester, PA), and
dimethylarsinic acid (Strem, Newburyport, MA). An AA/ICP solution containing 992 μg of
arsenic per ml in 0.2% HNO3 (Sigma–Aldrich) was the standard for total arsenic analysis by
hydride generation-atomic fluorescence spectrometry (HG-AFS).
2.2. Animal husbandry and treatments
Timed pregnant C3H/HeNCR mice obtained from the Animal Production Area, NCI-Frederick
(Frederick, MD) were housed in a standard barrier facility in a 12 h light/dark cycle at 68–72
F and a relative humidity of 50 ± 5%. Throughout treatment, mice had free access to basal diet
(NIH-31 Open Formula, 6% modified, Teklad, Madison, WI). Between gestational days 8 and
18, pregnant mice had free access to drinking water containing 42.5- or 85-ppm arsenic as
sodium arsenite (iAsIII). Addition of iAsIII at these dosage levels does not affect drinking water
consumption or weight gain as compared to responses in pregnant mice receiving drinking
water without added iAsIII (Waalkes et al., 2003). On gestational day 18, mice were euthanized
by CO2 asphyxiation and tissues collected for analysis of arsenic contents. Liver, lung, and
blood were collected from each of three pregnant females. Placentas were pooled for analysis.
Fetuses were processed to yield liver, lung, and blood samples. Blood was collected from
decapitated fetuses. All tissues were snap frozen in liquid nitrogen and stored at −70 °C until
analyzed.
2.3. Arsenic analysis
Speciated arsenicals in tissues were determined by HG-AAS as previously described (Devesa
et al., 2004). Tissues were prepared for analysis by overnight digestion at 90 °C in 3 ml of 2
M ultrapure phosphoric acid (J.T. Baker). Arsines were generated at pH 1 from a reaction
mixture containing 1% antifoam B silicone emulsion (1 ml), deionized water (7 ml), 6N HCl
(1 ml), and an aliquot of the digested tissue by addition of 1 ml of 4% NaBH4 in 0.02 M NaOH.
Generated arsines were swept in a helium stream (200 ml per min) to a U-tube containing
Chromosorb WAW-dimethyldichlorosilane 46/60 (Supelco, Inc., Bellefonte, PA) that was
immersed in liquid nitrogen. After a 3-min collection period, the U-tube was transferred from
liquid nitrogen to room temperature and warmed to allow boiling point-dependent release of
arsines. Arsines were carried into a quartz atomization cuvette in a Perkin-Elmer model 5100
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atomic absorption spectrometer. The cuvette was heated with an air (140 ml per min) and
hydrogen (610 ml per min) flame. Under these conditions, this method routinely resolves three
arsenicals (iAs, MAs, and DMAs). Four concentrations (2.5, 10, 20, 80 ng) of each of these
arsenicals were used to prepare calibration curves. Arsenicals in tissue samples were identified
by spiking samples with arsenical standards at several concentrations. Total speciated arsenic
concentration in a tissue sample was the sum of concentrations of iAs, MAs, and DMAs. To
assess recoveries of arsenicals in speciation analysis by HG-AAS, total arsenic contents of
mouse tissues were determined by HG-AFS using an automated ProStar 410 autosampler and
9012 quaternary pump (Varian Analytical Instruments, Palo Alto, CA, USA) with a
Millennium Excalibur HG-AFS system (PSAnalytical Ltd., Kent, England). HG-AFS analysis
was performed as previously described (Ma and Le, 1998). Briefly, tissues were completely
wet-digested by sequential addition of nitric and perchloric acid followed by sulfuric acid
(Devesa et al., 2004). Aliquots of digestates (100 μl) were injected into the hydride generator
in deionized water (3 ml per min), mixed with 5% HCl (1.9 ml per min), and then with 1.4%
NaBH4 (in 0.1 M NaOH, 1.9 ml per min). Arsines were carried in an Ar stream (235 ml per
min) to a fluorescence detector (Stockwell and Corns, 1994). Recovery of arsenic from a tissue
was calculated as total speciated arsenic concentration (determined by HG-AAS) divided by
the total arsenic concentration (determined by HG-AFS).
2.4. Statistical analysis
Differences between tissue concentrations of total speciated arsenic or of concentrations of
each of arsenic species in tissues of dams and fetuses in the two treatment groups were evaluated
by one-way analysis of variance (ANOVA) followed by a Tukey–Kramer multiple comparison
post-test. These analyses focused mainly on differences related to dosage level and on
differences in the concentrations of arsenicals in corresponding maternal and fetal tissues. A
GraphPad Instat software package (GraphPad Software Inc., San Diego, CA) was used for this
analysis. Differences at the p < 0.05 level were considered statistically significant.
3. Results
3.1. Tissue distribution of arsenicals
Concentrations of iAs, MAs, and DMAs were determined by HG-AAS in maternal and fetal
tissues collected on gestational day 18, at the end of a 10-day regimen of consumption of
drinking water that contained 42.5- or 85-ppm iAsIII. Compared to results from total arsenic
analysis by HG-AFS, recoveries of speciated arsenicals determined by HG-AAS ranged from
83% to 108% in liver, from 78% to 90% in lung, and from 84% to 123% in placenta. Mean
concentrations of total speciated arsenic in both maternal and fetal tissues from the 85-ppm
treatment group were consistently greater than in corresponding tissues from 42.5-ppm group
(Table 1). However, these differences were statistically significant only for maternal lung (p
< 0.01) and liver (p < 0.001). For the 42.5-ppm treatment group, mean total speciated arsenic
concentrations in maternal tissues and placenta did not differ significantly. In contrast, for the
85-ppm treatment group, mean total speciated arsenic concentrations in maternal lung and liver
were significantly greater than in placenta (p < 0.001). At either dosage level, total speciated
arsenic concentrations in maternal blood and placenta did not differ significantly. In general,
maternal tissues contained greater concentrations of total speciated arsenic than corresponding
fetal tissues. Statistically significant differences in total speciated arsenic concentrations in
corresponding maternal and fetal tissues occurred in lung in the 42.5-ppm treatment group
(p < 0.01) and in lung and in liver in the 85-ppm treatment group (p < 0.001). Comparing mean
total speciated arsenic concentrations in placenta with those in fetal tissues in both treatment
groups found no significant differences. Mean total speciated arsenic concentrations for liver,
lung, or blood did not differ significantly in male and female fetuses (data not shown).
Devesa et al. Page 4













Table 2 summarizes the percentages of total speciated arsenic present as iAs, MAs, or DMAs
in maternal and fetal tissues. In general, DMAs was the major metabolite, representing from
43.6% to 88.2% of total speciated arsenic in tissues. However, iAs and MAs represented
significant fractions of total speciated arsenic in maternal liver and blood, respectively.
Comparing percentages of speciated arsenicals for maternal and fetal tissues from the two
treatment groups found no significant differences related to arsenite dosage level. However,
there were significant differences between maternal and fetal tissues in proportions of some
metabolites. In both treatment groups, percentages of iAs and of DMAs in maternal and fetal
liver differed significantly (p < 0.001). The percentage of iAs was greater and the percentage
of DMAs was smaller in maternal than in fetal liver. Notably, iAs represented a greater
percentage of total speciated arsenic in maternal liver than in placenta (p < 0.01). For both
dosage levels, percentages of MAs and DMAs in maternal and fetal blood were also differed
significantly (p < 0.001) with maternal blood containing a higher percentage of MAs and a
lower percentage of DMAs than did fetal blood. The percentages of DMAs in placenta and in
fetal lung, liver, or blood differed significantly (p < 0.001) in the 85-ppm treatment group but
not in the 42.5-ppm treatment group. In the high dosage group, percentage of DMAs in all fetal
tissues consistently exceeded that found in placenta.
3.2. Concentration dependence of arsenic species in maternal and fetal tissues
For all tissues, relationships between concentrations of each arsenic species and total speciated
arsenic concentrations were examined (Fig. 1). Here, comparisons were made on a tissue
concentration basis, not based on iAs dosage level. In maternal lung, DMAs was the
predominant species over the entire range of total speciated arsenic concentrations. The relative
contributions of iAs, MAs, and DMAs to tissue arsenic burden in maternal liver changed as a
function of total speciated arsenic concentration. At low total speciated arsenic concentrations,
most tissue arsenic was DMAs. At higher total speciated arsenic concentrations, iAs
predominated. In maternal blood, roughly equal concentrations of MAs and DMAs were found
at lower total speciated arsenic concentrations; at higher concentrations, DMAs was
predominant. Maternal blood is the proximate source of arsenicals for transfer across placenta.
Thus, it is likely that the placenta and fetal mouse were exposed mostly to MAs and DMAs.
For both placenta and fetal tissues, DMAs was the predominant arsenical for all total speciated
arsenic concentrations. In these tissues, DMAs concentration increased proportionally to the
concentration of total speciated arsenic. Concentrations of arsenical species in placenta roughly
paralleled those in maternal blood. However, concentrations of arsenical species in fetal liver,
lung, and blood were consistently lower than concentrations in corresponding maternal tissues.
4. Discussion
Although considerable attention has been devoted to assessing the potential of iAs as a
teratogen or reproductive toxin (DeSesso et al., 1998), less emphasis has been placed on the
potential action of iAs or a metabolite as a transplacental carcinogen. However, the
transplacental exposure model for iAs used in this study has been definitively linked to
occurrence of cancers in several tissues (Waalkes et al., 2003,2004a). Hence, exposure in
utero to iAs or a metabolite leads to irreversible cellular transformation and a malignant
phenotype. These findings are consistent with the hypothesis that iAs or a metabolite crosses
the placenta and produces effects during a period of rapid growth and development when
susceptibility to the carcinogenic actions of many chemicals is heightened (Anderson et al.,
2000). As is typical in rodent carcinogenesis studies in which the number of exposed animals
is restricted by practical considerations, the present study used dosage levels of iAs which are
substantially higher than those commonly encountered in human population exposures. It
should be noted that comparing exposures in humans consuming iAs with those produced in
the mouse model used in the present study is problematic. In an Argentinian population
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consuming water containing about 200 ppb of iAs, maternal blood collected in late gestation
contained about 11 mu;g per l (Concha et al., 1998). By comparison, blood collected from
pregnant mice at the end of gestational exposure to iAs contained 25–75 times higher
concentrations of As. Hence, it is reasonable to conclude that doses of iAs and its metabolites
attained in the mouse model exceeded by many-fold those found in human populations.
Nevertheless, in populations that use drinking water supplies containing over 1 ppm of iAs
(Guha Mazumder et al., 1998), high in utero exposures to iAs or its metabolites could contribute
to the increased risk of cancer that has been associated with chronic exposure to iAs. Because
little is known about the pattern and extent of exposure of fetal mice to iAs or its metabolites,
this study quantified arsenicals in maternal and fetal tissues, examined dosage dependency of
arsenical accumulation in maternal and fetal tissues, and determined relative contributions of
each arsenical to total arsenic burdens of maternal and fetal tissues.
Although concentrations of total speciated arsenicals in maternal lung and liver were
significantly different between dosage groups, in other maternal and fetal tissues there were
no significant dosage dependencies for concentrations of total speciated arsenicals. These
deviations from expected patterns of dosage dependency for tissue distribution of arsenicals
may reflect differences in both kinetic and dynamic factors that affect the metabolism and
disposition of arsenite and its metabolites, particularly at high dosage levels used in these
studies. The lack of significant dosage-dependent differences could also reflect the small
sample size or high variability in the measured concentrations of arsenicals. Significant
differences between concentrations of total speciated arsenicals in maternal and fetal tissues
suggested that placenta limits transfer or accumulation of arsenicals. Studies of tissue
distribution of arsenic in rats (Tanaka, 1976) and mice (Gerber et al., 1982; Hood et al.,
1988) following iAs exposure in utero found higher arsenic concentrations in placenta than in
fetal tissues. Although not significantly different, lower concentrations of total speciated
arsenicals in fetal tissues than in placenta were also consistent with the function of the placenta
as a barrier affecting the transfer of inorganic arsenic or its metabolites from mother to fetus.
For both maternal and fetal tissues, differences between dosage groups in percentages of the
total speciated arsenic concentrations accounted for by iAs, MAs, or DMAs were not
significant. However, there were significant differences in proportions of these arsenicals in
maternal and fetal tissues. Because iAs, MAs, and DMAs are linked in a precursor,
intermediate, and product relationship, a change in the relative proportion of one arsenical
species must be accompanied by change in the concentration of one or both of the other
arsenicals. Hence, in both dosage groups, significant differences occurred in percentages of
iAs and DMAs in maternal and fetal liver. Significant changes also occurred in percentages of
MAs and DMAs present in maternal and fetal blood in both dosage groups. Differences in
proportions of arsenicals in maternal and fetal tissues could arise in differences in disposition,
formation, or retention of these metabolites. For example, the predominance of DMAs in fetal
tissues might reflect its relative abundance in maternal blood, its preferential transfer across
placenta, or its preferential retention in fetal tissues.
Notably, an earlier study in fetal mice exposed transplacentally to iAs found DMAs to be the
predominant arsenical present in fetuses but did not provide data on distribution of iAs and its
metabolites in fetal tissues (Hood et al., 1987). Accumulation and retention of DMAs in fetal
tissues could reflect an unusual affinity of some tissue constituent for DMAs. Preferential
accumulation of DMAs occurs in lungs of rodents exposed to iAs or DMAs (Marafante et al.,
1987; Hughes et al., 2000; Kenyon et al., 2005). Accumulation of DMAs in lung produces
morphological changes and cellular toxicity (Yamanaka and Okada, 1994; Kato et al., 2000),
although, critical molecular targets in tissues for iAs and its metabolites have not been
identified. Accumulation of DMAs in fetal tissues could be a consequence of its formation in
placenta or in fetal tissues. Although systematic data are lacking on the ontogeny of arsenic
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methylation in the developing mouse, the homologous AS3MT gene in the mouse (Li et al.,
2005) could catalyze metabolism of arsenicals in fetal tissues. AS3MT mRNA has been
detected in mouse fetuses and embryos (http://cgap.nci.nih.gov/SAGE/mSEM); however,
additional information on AS3MT mRNA and protein levels and on activities in fetal tissues
are needed to assess the contribution of arsenic methylation capacity to the accumulation of
DMAs during gestation.
The pattern of metabolites found in tissues might also reflect a concentration-dependent change
in capacity for enzymatic production of methylated metabolites. In this study, the changing
pattern of arsenicals in maternal liver as a function of total speciated arsenical concentration
may reflect concentration-dependent changes in capacity of liver to convert iAs to methylated
metabolites. Tissue concentrations of methylated arsenicals and pattern and extent of excretion
of these metabolites in urine have been reported to be dose dependent in mice that received
iAsV or iAsIII (Hughes et al., 1994, 1999; Csanaky et al., 2003). Patterns of metabolite
formation in cultured primary rat or human hepatocytes exposed to iAsIII show that formation
of DMAs from MAs is inhibited at high substrate concentration (Styblo et al., 1999; Drobná
et al., 2004; Easterling et al., 2002). Thus, a decreased level of DMAs in maternal liver at high
levels of exposure may be linked to high concentrations of iAs and MAs which inhibit
enzymatically catalyzed formation of DMAs.
Aberrant patterns of gene expression in adult mice may be a consequence of in utero exposure
to iAs. Tumorous and non-tumorous tissue from livers of adult male mice exposed in utero to
iAs show aberrant patterns for expression of genes involved in cell differentiation and
proliferation (Liu et al., 2004). Because arsenicals are cleared from tissues with half times of
a few days (Hughes et al., 2003), persistent alterations of gene expression in the tissues of
mature mice may reflect changes in gene programming caused by early life exposure to iAs or
a metabolite. An altered pattern of methylation of DNA induced by exposure to iAs or a
metabolite in utero is one plausible mechanism for an effect on gene expression. For example,
hypomethylation of the promoter region of the estrogen receptor α (ER-α) gene in livers of
adult male mice that were exposed in utero to iAs has been linked to elevated ER-α mRNA
levels and is consistent with a feminized pattern of gene expression in livers of these mice
(Waalkes et al., 2004c). Aberrant ER-α gene expression induced by exposure in utero to iAs
probably contributes to increased incidence of urogenital tract tumors found in female mice
treated postnatally with diethylstilbestrol (Waalkes et al., 2006). Global DNA hypomethylation
has also been observed in livers of adult male mice chronically exposed to iAs in drinking
water (Chen et al., 2004). These finding suggest that increased demand for AdoMet to serve
as a methyl group donor for methylation of high concentrations of iAs affects the ability of
cells to meet the demand for AdoMet-derived methyl groups for the maintenance of the normal
pattern of DNA methylation. Indeed, a competition for methyl group donation from AdoMet
might be the molecular locus for a critical effect of arsenic on gene expression (Goering et al.,
1999). Because altered patterns of DNA methylation contribute to development or progression
of malignant tumors (Davis and Uthus, 2004), this effect could underlie malignant
transformations seen in tissues of mice long after in utero exposure to iAs or its metabolites
has ended. Although iAs and it metabolites, MAs and DMAs, were found in fetal tissues that
are targets for tumor development in later life, the arsenical species responsible for
transplacental carcinogenesis has not been determined. DMAs, the most abundant arsenical in
fetal tissues, is a complete carcinogen and a promoter in adult rats (Yamamoto et al., 1995;
Wei et al., 1999) and a promoter in adult mice (Mizoi et al., 2005). Additional studies of the
disposition of DMAs and other intermediates and products in the pathway for arsenic
methylation using the transplacental exposure model in the mouse may identify critical species
and clarify molecular processes that underlie these adverse effects.
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Relationship between concentrations of total speciated arsenic and concentrations of each
arsenical species in maternal and fetal tissues. Data shown for inorganic arsenic (■, □), methyl
arsenic (●, ○), and dimethyl arsenic (▲, △) in tissues. Filled symbols are data from maternal
and fetal tissues from the 42.5 ppm arsenic dosage group; open symbols are from the 85 ppm
arsenic dosage group.
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Table 1
Dosage level dependence of concentrations of total speciated arsenicals in maternal and fetal mouse tissuesa
Concentration of inorganic As in drinking water
42.5 ppm 85 ppm










Fetal lung 292.6e 417.6f
136.7 65.8
Fetal liver 293.2 504g
88 98.2
Fetal blood 206.2 447.7
123.6 142.8
a–j
Values labeled with the same letter are significantly different (p < 0.05).
a
Concentration of total speciated arsenic in tissues expressed as ng of arsenic per g of tissue. Mean (upper) and standard deviation (lower) shown. For
each dosage level, n = 3; for maternal tissues and n = 5 or 6 for placentas and fetal tissues.
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